Login to Your Account

Genkyotex Pulls in $26M to Advance Its NOX Inhibitor

By Nuala Moran
Staff Writer

Wednesday, July 11, 2012
LONDON – Genkyotex SA has raised CHF25 million (US$26 million) as an extension to its Series C, with the existing investors all following on to fund Phase II development of the lead compound, GKT137831 in diabetic nephropathy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription